HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial
JNCI Monographs · 01.11.2024 · 2024 (67) · 329-336
DOI: 10.1093/jncimonographs/lgae032 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JNCI Monographs, online erschienen am 12.11.2024. Verfasst von Carolina Porras und 15 weiteren Autor:innen. Beteiligte Einrichtung: Agencia Costarricense de Investigaciones Biomédicas, San José, Costa Rica. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Human papillomavirus 16, Human papillomavirus 18, Papillomavirus Infections. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, GlaxoSmithKline Biologicals, Office of Research on Women's Health.
Abstract (Originalsprache)
Background
The Costa Rica HPV Vaccine Trial provided initial evidence that 1 dose of the bivalent human papillomavirus (HPV) vaccine induces stabilizing antibody levels that may provide extended protection against HPV-16/18 infections. We report antibody seropositivity and stability 11 to 16 years after vaccination.
Methods
We invited a random subset of Costa Rica HPV Vaccine Trial participants (n = 398) who had received 3 doses and all women (n = 203) who had received 1 dose at 18 to 25 years of age to follow-up visits 11, 14, and 16 years after vaccination. We calculated HPV-16 and HPV-18 seropositivity and assessed change in enzyme-linked immunosorbent assay antibody levels 11 to 16 years after vaccination among 500 participants.
Results
By year 16, 99.4% (95% confidence interval [CI] = 96.8% to 100.0%) and 100.0% (95% CI = 98.9% to 100.0%) of 1-dose and 3-dose recipients, respectively, were HPV-16 seropositive and 98.8% (95% CI = 95.9% to 99.9%) and 100% (95% CI = 98.9% to 100.0%) of 1-dose and 3-dose recipients, respectively, were HPV-18 seropositive. Between years 11 and 16, women who had received 3 doses had a small but statistically significant decrease in the geometric mean concentration for HPV-16 of ‒12.4% (95% CI = ‒16.3% to ‒8.4%) and HPV-18 of ‒13.4% (95% CI = ‒17.2% to ‒9.4%). Among women who had received 1 dose, the decrease was statistically significant for HPV-16 at ‒8.9 (95% CI = ‒14.2% to ‒3.1%) but nonsignificant for HPV-18. Geometric mean concentration ratios of 3:1 dose (year 16) were 3.0 and 2.2 for HPV-16 and HPV-18, respectively.
Conclusions
HPV-16/18 seropositivity remained exceedingly high 16 years after vaccination. Over 5 years, small declines in antibodies were observed. Women should have protection for at least 20 years and likely much longer at the observed rate of decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Agencia Costarricense de Investigaciones Biomédicas, San José, Costa Rica.
- Frederick National Laboratory, Frederick, MD, USA.
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
- Information Management Services, Silver Spring, MD, USA.
- Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
ORCID-Profile: Carolina Porras
Förderung
- NCI NIH HHS
- GlaxoSmithKline Biologicals
- Office of Research on Women's Health
- NIH HHS
- US Food and Drug Administration BB-IND
- National Cancer Institute
- National Institutes of Health
- Office of Research on Women’s Health
Zitieren
APA
Porras, C., Romero, B., Kemp, T., Fantin, R., Herrero, R., Hildesheim, A., Ocampo, R., Sierra, M. S., Gail, M. H., Schussler, J., Schiller, J. T., Lowy, D. R., Pinto, L. A., Liu, D., Kreimer, A. R., & Costa Rica HPV Vaccine Trial Study Group (2024). HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial. JNCI Monographs, 2024(67), 329-336. https://doi.org/10.1093/jncimonographs/lgae032
Vancouver
Porras C, Romero B, Kemp T, Fantin R, Herrero R, Hildesheim A, et al. HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial. JNCI Monographs. 2024;2024(67):329-336. doi:10.1093/jncimonographs/lgae032
BibTeX
@article{Porras2024,
author = {Porras, Carolina and Romero, Byron and Kemp, Troy and Fantin, Romain and Herrero, Rolando and Hildesheim, Allan and Ocampo, Rebeca and Sierra, Mónica S and Gail, Mitchell H and Schussler, John and Schiller, John T and Lowy, Douglas R and Pinto, Ligia A and Liu, Danping and Kreimer, Aimée R and Costa Rica HPV Vaccine Trial Study Group, Costa Rica HPV Vaccine Trial Study Group},
title = {HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial},
journal = {JNCI Monographs},
year = {2024},
volume = {2024},
number = {67},
pages = {329--336},
doi = {10.1093/jncimonographs/lgae032}
}
EUVIMED